The story has been updated to include comments from Qiagen's conference call on Wednesday morning.

NEW YORK (GenomeWeb) – Qiagen reported after the close of the market on Tuesday that its second quarter sales rose 5 percent year over year, matching consensus analysts' estimates on the top and bottom lines.

Qiagen recorded sales of $330.8 million, up from $315.2 million during the year-ago quarter, and on par with the average Wall Street estimate. It said that its adjusted net sales were $331.2 million, up 5 percent from $316.4 million for Q2 2013.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.